Vildagliptin
- Generic Name
- Vildagliptin
- Brand Names
- Galvus, Jalra, Xiliarx
- Drug Type
- Small Molecule
- Chemical Formula
- C17H25N3O2
- CAS Number
- 274901-16-5
- Unique Ingredient Identifier
- I6B4B2U96P
- Background
Vildagliptin (LAF237) is an orally active antihyperglycemic agent that selectively inhibits the dipeptidyl peptidase-4 (DPP-4) enzyme. It is used to manage type II diabetes mellitus, where GLP-1 secretion and insulinotropic effects are impaired. By inhibiting DPP-4, vildagliptin prevents the degradation of glucagon-like peptide 1 (GLP-1) and glucose-dependen...
- Indication
Vildagliptin is indicated in the treatment of type II diabetes mellitus in adults. As monotherapy, vildagliptin is indicated in adults inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. It is also indicated as dual therapy in combination with metformin, a sulphonylurea, or a thi...
- Associated Conditions
- Type 2 Diabetes Mellitus
- Associated Therapies
- -
Galvus (Vildagliptin) vs Placebo in Combination With Metformin and Insulin
- First Posted Date
- 2012-12-31
- Last Posted Date
- 2015-07-30
- Target Recruit Count
- 39
- Registration Number
- NCT01757587
- Locations
- 🇫🇷
CH Sud Francilien, Evry, France
Efficacy and Safety Comparative Study of Sitagliptin,Vildagliptin and Saxagliptin
- Conditions
- Interventions
- First Posted Date
- 2012-10-10
- Last Posted Date
- 2016-03-31
- Lead Sponsor
- Lin Liao
- Target Recruit Count
- 300
- Registration Number
- NCT01703637
- Locations
- 🇨🇳
YuCheng people's hospital, Dezhou, Shandong, China
🇨🇳Hospital of SINOTRUK, Jinan, Shandong, China
🇨🇳Jinan central hospital, Jinan, Shandong, China
Vildagliptin vs Sitagliptin add-on to Insulin - Impact on Glycemic Profile and Correlation of Hypoglycemic Episodes and Heart Function
- First Posted Date
- 2012-09-18
- Last Posted Date
- 2016-03-02
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 51
- Registration Number
- NCT01686932
- Locations
- 🇩🇪
Novartis Investigative Site, Wallerfing, Germany
Effect of Anti-diabetic Drugs on Bone Metabolism and Glycemic Variability
- Conditions
- Interventions
- First Posted Date
- 2012-09-06
- Last Posted Date
- 2016-11-04
- Lead Sponsor
- Centro de Diabetes Curitiba Ltda
- Target Recruit Count
- 56
- Registration Number
- NCT01679899
- Locations
- 🇧🇷
Centro de Diabetes Curitiba, Curitiba, Parana, Brazil
DPP-IV Inhibitors Underlying Mechanism of Cancer in Diabetic Patients
- Conditions
- Interventions
- First Posted Date
- 2012-05-01
- Last Posted Date
- 2012-10-19
- Lead Sponsor
- Nagaoka Red Cross Hospital
- Target Recruit Count
- 500
- Registration Number
- NCT01588587
- Locations
- 🇯🇵
Kurume University, Kurume, Fukuoka, Japan
🇯🇵Nagaoka Red Cross Hospital, Nagaoka, Niigata, Japan
Efficacy and Safety of Vildagliptin 50mg Bid as an add-on Therapy to Insulin With or Without Metformin, in Patients With Type 2 Diabetes Mellitus
- First Posted Date
- 2012-04-20
- Last Posted Date
- 2013-08-30
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 293
- Registration Number
- NCT01582230
- Locations
- 🇹🇭
Novartis Investigative Site, Khon Kaen, Thailand
Safety and Efficacy of Vildagliptin Plus Metformin (SPC) Treatment in Type 2 Diabetes Mellitus Patients
- First Posted Date
- 2012-04-20
- Last Posted Date
- 2016-11-03
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 40
- Registration Number
- NCT01582243
- Locations
- 🇨🇳
Novartis Investigative Site, Changhua, Taiwan
Effect of Adding Vildagliptin on Beta Cell Function and Cardiovascular Risk Markers in Patients With Moderate Metabolic Control During Metformin Monotherapy
- Conditions
- Interventions
- First Posted Date
- 2012-03-28
- Last Posted Date
- 2012-03-28
- Lead Sponsor
- ikfe-CRO GmbH
- Target Recruit Count
- 44
- Registration Number
- NCT01565096
- Locations
- 🇩🇪
ikfe GmbH, Mainz, Germany
Evaluation of Vildagliptin (Galvus®) as add-on to Insulin in New-onset Type 1 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2012-03-20
- Last Posted Date
- 2014-05-14
- Lead Sponsor
- Federal University of São Paulo
- Target Recruit Count
- 44
- Registration Number
- NCT01559025
- Locations
- 🇧🇷
Federal University of São Paulo, São Paulo, Brazil
Efficacy of VIldagliptin aS an Add-on Therapy to Metformin Compared to Metformin Up-TitratION in Chinese Patients With Type 2 Diabetes.(VISION)
- First Posted Date
- 2012-03-01
- Last Posted Date
- 2016-11-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 3091
- Registration Number
- NCT01541956
- Locations
- 🇨🇳
Novartis Investigative Site, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.